Marker Therapeutics Inc Total Assets
Marker Therapeutics Inc total assets. Based on the latest financial reports, Marker Therapeutics Inc (MRKR) holds total assets worth $14.59 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MRKR market cap for the company's overall valuation and market capitalisation.
Total Assets of Marker Therapeutics Inc (1999–2025)
Total assets of Marker Therapeutics Inc from 1999 to 2025. This chart illustrates how Marker Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See today's stock price for Marker Therapeutics Inc for real-time trading data and today's change.
Marker Therapeutics Inc - Asset Composition Analysis
Marker Therapeutics Inc Total Assets Breakdown (December 2025)
Marker Therapeutics Inc total assets breakdown as of December 2025. Marker Therapeutics Inc's total assets of $14.59 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 84.3% |
| Accounts Receivable | $1.37 Million | 7.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2025)
This chart illustrates how Marker Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Marker Therapeutics Inc current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Marker Therapeutics Inc's current assets represent 100.0% of total assets in 2025, an increase from 64.2% in 1999.
- Cash Position: Cash and equivalents constituted 84.3% of total assets in 2025, up from 29.4% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 7.2% of total assets.
Marker Therapeutics Inc Competitors by Total Assets
Key competitors of Marker Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Marker Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.03 | 3.45 | 6.25 |
| Quick Ratio | 6.03 | 3.45 | 6.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $12.17 Million | $10.49 Million | $43.18 Million |
Marker Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Marker Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.62 |
| Latest Market Cap to Assets Ratio | 0.86 |
| Asset Growth Rate (YoY) | -13.4% |
| Total Assets | $19.07 Million |
| Market Capitalization | $16.39 Million USD |
Valuation Analysis
Near Book Valuation: The market values Marker Therapeutics Inc's assets close to their book value (0.86x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Marker Therapeutics Inc's assets decreased by 13.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Marker Therapeutics Inc (1999–2025)
The table below shows the annual total assets of Marker Therapeutics Inc from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $19.07 Million | -13.40% |
| 2024-12-31 | $22.02 Million | +28.58% |
| 2023-12-31 | $17.13 Million | -50.24% |
| 2022-12-31 | $34.42 Million | -49.48% |
| 2021-12-31 | $68.14 Million | +49.37% |
| 2020-12-31 | $45.61 Million | -1.61% |
| 2019-12-31 | $46.36 Million | -25.40% |
| 2018-12-31 | $62.14 Million | +1099.60% |
| 2017-12-31 | $5.18 Million | -34.60% |
| 2016-12-31 | $7.92 Million | +19.20% |
| 2015-12-31 | $6.65 Million | +2860.76% |
| 2014-12-31 | $224.45K | +191.37% |
| 2013-12-31 | $77.03K | -26.08% |
| 2012-12-31 | $104.21K | -69.37% |
| 2011-12-31 | $340.21K | +192.20% |
| 2010-12-31 | $116.43K | -67.38% |
| 2009-12-31 | $356.96K | +574.68% |
| 2008-12-31 | $52.91K | -81.04% |
| 2007-12-31 | $279.11K | +80.84% |
| 2006-12-31 | $154.34K | +71.75% |
| 2005-12-31 | $89.86K | +1.90% |
| 2004-12-31 | $88.19K | -5.39% |
| 2003-12-31 | $93.21K | -87.76% |
| 2002-12-31 | $761.43K | +530.39% |
| 2000-12-31 | $120.79K | -18.54% |
| 1999-12-31 | $148.28K | -- |
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-assoc… Read more